Table 3.
Study Specimen Collection, RSV Prevalence Results, and Sensitivity by Specimen Type for Cases
| Study Specimen | No. | % With This Specimen Type | RSV Positive by Specimen, No. (%) | % of All Positives Identified by This Specimen Type (95% CI) | RSV Positive From Any Source Among Patients With Specimen Type, No. | Sensitivitya (95% CI) |
|---|---|---|---|---|---|---|
| Overall | 1558 | 100.0 | 92 (5.9) |
… | 92 | … |
| Study PCR | 1558 | 100.0 | 69 (4.4) |
75.0 (66.2–83.8) | 92 | 75.0 (66.2–83.8) |
| NP/OP | 1558 | 100.0 | 58 (3.7) |
63.0 (53.1–72.9) | 92 | 63.0 (53.1–72.9) |
| NP | 742 | 47.6 | 10 (1.4) |
10.9 (4.5–17.3) | 16 | 62.5 (38.8–86.2) |
| OP | 740 | 47.5 | 3 (0.4) |
3.3 (−.4 to 7.0) | 16 | 18.8 (−.3 to 37.9) |
| SOC NP PCR | 805 | 51.7 | 58 (7.2) |
63.0 (53.1–72.9) | 65 | 89.2 (81.7–96.7) |
| Serology | 568 | 36.5 | 28 (4.9) |
30.4 (21.0–39.8) | 46 | 60.9 (46.8–75.0) |
| Acute specimen collected ≤5 d from symptom onset | 361 | 23.2 | 14 (3.9) |
15.2 (7.9–22.5) | 24 | 58.3 (38.6–78.0) |
| Acute specimen collected >5 d from symptom onset | 207 | 13.3 | 14 (6.8) |
15.2 (7.9–22.5) | 22 | 63.6 (43.5–83.7) |
| Serology 1 | 568 | 36.5 | 19 (3.4) |
20.6 (12.3–28.9) | 46 | 41.3 (27.1–55.5) |
| Serology 2 | 268 | 17.2 | 16 (6.0) |
17.4 (9.7–25.1) | 27 | 59.2 (40.7–77.7) |
| Sputum | 153 | 9.8 | 5 (3.3) |
5.4 (.8–10.0) | 5 | 100.0 (100–100) |
Study PCR represents all who had a research specimen (combined NP/OP or stand-alone NP or OP) tested by BioFire respiratory panel. SOC represents all who had SOC nucleic acid amplification testing of an NP specimen for RSV. Serology 1 represents IgG binding to RSV lysate as measured by ELISA. Serology 2 represents IgG binding to either RSV F, G, M, or N by multiplexed serology platform. Sputum represents all who had an expectorated sputum sample available for BioFire respiratory panel analysis.
Abbreviations: ELISA, enzyme-linked immunosorbent assay; IgG, immunoglobulin G; NP, nasopharyngeal; OP, oropharyngeal; PCR, polymerase chain reaction; RSV, respiratory syncytial virus; SOC, standard-of-care.
aSensitivity is limited to those with results with that specimen type, ie, count of positives by that specimen type divided by count of all positives from any source among those with results by that specimen type.